Company Overview

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The International segment offers distribution and services to wholesale, institutional, and retail customers in 13 European countries and Canada. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The RxTS segment serves biopharma and life sciences partners and patients to address medication challenges for patients throughout their journeys; connects pharmacies, providers, payers, and biopharma companies to deliver innovative access and adherence solutions; and provides third-party logistics and wholesale distribution support solutions. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.

  • Name

    McKesson Corporation

  • CEO

    Mr. Brian S. Tyler Ph.D.

  • Website

    www.mckesson.com

  • Sector

    Health Care Providers and Services

  • Year Founded

    1833

Profile

  • Market Cap

    $65.38B

  • EV

    $70.89B

  • Shares Out

    129.68M

  • Revenue

    $313.75B

  • Employees

    48,000

Margins

  • Gross

    4.05%

  • EBITDA

    1.64%

  • Operating

    1.47%

  • Pre-Tax

    1.21%

  • Net

    0.94%

  • FCF

    1.12%

Returns (5Yr Avg)

  • ROA

    1%

  • ROTA

    -158.21%

  • ROE

    -93.91%

  • ROCE

    22.28%

  • ROIC

    14.97%

Valuation (TTM)

  • P/E

  • P/B

  • EV/Sales

  • EV/EBITDA

  • P/FCF

  • EV/Gross Profit

Valuation (NTM)

  • Price Target

    $619.53

  • P/E

  • PEG

  • EV/Sales

  • EV/EBITDA

  • P/FCF

Financial Health

  • Cash

    $2,302M

  • Net Debt

    $5,134M

  • Debt/Equity

    -5.38

  • EBIT/Interest

    16.43

Growth (CAGR)

  • Rev 3Yr

    8.56%

  • Rev 5Yr

    7.61%

  • Rev 10Yr

    7.76%

  • Dil EPS 3Yr

    -7.58%

  • Dil EPS 5Yr

    48.63%

  • Dil EPS 10Yr

    15.41%

  • Rev Fwd 2Yr

    11.31%

  • EBITDA Fwd 2Yr

    9.97%

  • EPS Fwd 2Yr

    14.26%

  • EPS LT Growth Est

    12.02%

Dividends

  • Yield

  • Payout

    11.04%

  • DPS

    $2.48

  • DPS Growth 3Yr

    13.86%

  • DPS Growth 5Yr

    9.71%

  • DPS Growth 10Yr

    9.96%

  • DPS Growth Fwd 2Yr

    9.87%

NYSE:MCK